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ABSTRACT
The global burden of pneumococcal diseases is
high, with young children and adults C50 years
of age at highest risk of infection. Two types of
vaccine are available for the prevention of
pneumococcal diseases caused by specific
Streptococcus pneumoniae serotypes: the
pneumococcal polysaccharide vaccine (PPV23)
and the pneumococcal conjugate vaccine
(PCV7, PCV10, and PCV13). Despite
pneumococcal immunization programs in
adults and children, the burden in adults has
remained high. Most European countries have
national or local/regional vaccination
recommendations. The objective of this review
was to provide an overview of the government
recommendations for pneumococcal
vaccination outside routine childhood
vaccination programs for 16 Western European
countries as of August 2014. We found that
recommendations for pneumococcal
immunization across Europe are complex and
vary greatly among countries in terms of age
groups and risk groups recommended for
vaccination, as well as which vaccine should
be administered. Clarifying or simplifying these
recommendations and improving their
dissemination could help to increase
pneumococcal vaccine uptake and decrease
the high burden of pneumococcal diseases in
adults, both through a direct effect of the
vaccine and via a herd effect in unvaccinated
individuals.
Keywords: Age; Europe; Immunization;
Infectious diseases; Pneumococcal conjugate




Pneumococcal infection causes a spectrum of
diseases from mild presentations such as
sinusitis and otitis media, to more serious
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diseases such as meningitis, bacteremia, and
pneumonia [1]. The 23-valent pneumococcal
polysaccharide vaccine (PPV) was introduced in
1983 and is available in Europe for
immunization against pneumococcal diseases
caused by the 23 serotypes contained in the
vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A,
12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F,
and 33F) in adults and children aged C2 years
[2]. The first pneumococcal conjugate vaccine
(PCV7) was licensed in 2000 for immunization
against pneumococcal diseases, including
sepsis, meningitis, pneumonia, bacteremia,
and acute otitis media (AOM) caused by the
seven serotypes contained in the vaccine (4, 6B,
9V, 14, 18C, 19F, and 23F) in infants and
children aged 2 months to 5 years [3]. PCV10
(serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and
23F) was approved in 2009 for protection
against invasive pneumococcal disease (IPD),
pneumonia, and AOM in infants and children
aged from 6 weeks up to 5 years [4]. A higher-
valent PCV, PCV13, comprising six additional
serotypes to PCV7 (serotypes 1, 3, 5, 6A, 7F, and
19A) is now available in Europe for the
prevention of IPD in adults aged C18 years,
and for the prevention of IPD, pneumonia, and
AOM in infants and children aged between
6 weeks and 17 years [5].
The global burden of pneumococcal diseases
is high, with young children and adults
C50 years of age at particular risk of infection.
In the 1990s, the age groups with the highest
incidence of IPD and highest case fatality rates
were infants aged \2 years and adults aged
[50 years [6]. Routine childhood pneumococcal
immunization programs have helped to
alleviate the burden of disease in children [7,
8]. Since 2006, the World Health Organization
(WHO) has recommended that PCV be included
in all routine childhood immunization
programs [9]. Consequently, PCV use has
increased from 1% of all WHO member states
in 2000 to 44% in 2012, representing 31% of the
global birth cohort [9]. Of the European region
member states, 49% had introduced PCV by
2012 [9]. Over time the benefits of childhood
vaccination with PCV in countries with high
uptake have extended to unvaccinated children
and adults as a result of the herd effect [10–13].
However, despite pneumococcal immunization
programs covering adults and children, the
burden in adults has remained high [14].
Recommendations for pneumococcal
immunization across Europe are complex and
are regularly updated. The objective of this
review is to provide an overview of current
government recommendations (not including
scientific society recommendations), both
national and regional where applicable,
outside routine pneumococcal immunization
programs for infants and children, in 16
individual countries across Western Europe
(Austria, Belgium, Denmark, Finland, France,
Germany, Greece, Ireland, Italy, Luxembourg,
The Netherlands, Norway, Portugal, Spain,
Sweden, and the United Kingdom [UK]), as of
August 2014. A summary of the
recommendations is provided in the text
below, with more detailed information
supplied for reference purposes in Table 1. To
ensure the most up-to-date information for
each country was included, Pfizer’s country
Medical Affairs offices provided information
regarding national and regional
recommendations for pneumococcal
vaccination. This article is based on pre-
existing source material and does not include
any studies with human or animal subjects






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In addition to routine pneumococcal
immunization programs in infants and
children, most countries across Europe have
further local or national recommendations
(Table 1). Those without such
recommendations may follow other
guidelines, such as society guidelines or those
from the Advisory Committee on
Immunization Practices (ACIP; e.g., The
Netherlands). Although generally falling
within the prescribing information for the
vaccines, pneumococcal immunization
practices differ across Europe with regards to
age groups and risk groups immunized, which
vaccine (PPV versus PCV) is advised for which
groups, and eligibility for reimbursement. The
majority of the 16 Western European countries
included in this article implement
immunization programs with both age-based
and risk-based elements. PPV23 is widely
recommended across Western Europe;
however, many countries have now included
PCV in their pneumococcal immunization
recommendations for certain groups of
children and adults, either alone or in
addition to PPV23. Figure 1 details the current
adult national recommendations and
reimbursement of PCV13.
Age-Based Elements of Pneumococcal
Immunization Programs
Age-based recommendations (usually for older
adults) form part of the full immunization
programs across most countries in Western
Europe. However, the recommended vaccine
and the age group eligible for vaccination vary
between countries (Table 1). For example,
immunization programs recommending PPV23
are implemented in Luxembourg (age
[60 years), Finland, Ireland, Norway, Sweden,
UK (all age C65 years), and most autonomous
regions of Spain (age C60/C65 years).
Immunization programs recommending PCV
exist in Greece (PCV13; [50 years), Germany
(Saxony only; PCV; C60 years), Denmark
(PCV13; C65 years), and some regions of Italy,
including Tuscany (PCV13; C50 years),
Basilicata, Bolzano, and Trento (all PCV13; [65
or C65 years), Liguria (PCV13;[70 years), Puglia
(PCV13; cohorts 65, 70, 75 years), and Sicilia
(PCV13; cohorts 65, 75 years). Additionally, age-
based immunization programs recommending
PCV and/or PPV23 exist in Austria, Belgium, and
some regions of Italy.
Risk-Based Elements of Pneumococcal
Immunization Programs
Some countries/regions across Western Europe
advise pneumococcal immunization in
individuals with specific co-morbidities that
are considered to place them at an increased
risk of pneumococcal diseases, regardless of age.
Such purely risk-based elements are
implemented in the pneumococcal
immunization programs in Denmark, Norway,
Sweden, UK, and some regions of Italy
(Basilicata, Bolzano, Emilia Romagna, Lazio,
Liguria, Marche, Trento, and Veneto; see
Table 1 for specific risk groups and
recommended vaccines).
Risk-based elements of pneumococcal
immunizations programs across Europe can be
very complex. For example, the risk groups
eligible for vaccination can vary by age group
(e.g., Belgium, Denmark, France, Germany,
Adv Ther
Ireland, Luxembourg, Spain [Murcia], and the
UK), different vaccines may be advised for
different risk groups (e.g., Finland, France,
Ireland, Norway, and the UK) or different
vaccines may be advised in different age
groups considered to be at risk of
pneumococcal diseases (e.g., France, Germany,
Ireland, Luxembourg, and Portugal). Many
European countries/regions advise vaccination
with both PCV and PPV23 in individuals at risk
of pneumococcal diseases (see the Additional
information column in Table 1). However, PCV
is preferred over PPV23 in individuals at risk of
pneumococcal diseases in Finland (all high-risk
individuals) and France (immunosuppressed
and asplenic individuals).
Fig. 1 European national recommendations and reimbursement of 13-valent pneumococcal conjugate vaccine (PCV13) in
adults
Adv Ther
Heterogeneity in the Definition
of Individuals Considered to be at Risk
of Pneumococcal Diseases
There is a marked variation between countries
concerning which individuals are considered to
be at risk of pneumococcal diseases and their
eligibility for immunization, with some
countries including many more medical
conditions (e.g., Austria, Ireland, and Portugal)
than others (e.g., Norway and national
recommendations for Spain). Consistent with
the ACIP recommendations for immunization
of children and adults at risk of pneumococcal
diseases [15, 16], common conditions
considered to place individuals at an increased
risk in Europe include underlying co-
morbidities such as chronic kidney (risk
category in adults only), heart, liver or
respiratory disease, metabolic diseases (e.g.,
diabetes mellitus), central nervous system
diseases (e.g., cerebrospinal fluid leak) and
immunocompromised individuals, including
human immunodeficiency virus (HIV)-positive
individuals, primary immunodeficiency, organ
transplantation, asplenia (functional or
anatomical), and hematological cancer. Other
risk factors less commonly included are
previous IPD (Denmark, Ireland [children
under the age of 5 years], Italy [Lombardia],
Spain [Murcia and Basque Country], and
Sweden) and lifestyle risk factors such as
alcoholism (Belgium, Ireland, Italy [Bolzano
and Emilia Romagna], Luxembourg, Spain
[Madrid and all autonomous regions], and
Sweden), smoking (Belgium and Ireland), and
residing in a nursing home or permanent
institution (Finland, Italy [Emilia Romagna,
Trento, Tuscany, Umbria], Luxembourg, and
Spain [all autonomous regions]). Most European
countries recommend initial vaccination with
PCV13 for individuals at risk of pneumococcal
diseases, followed by PPV23 vaccination
C8 weeks later. Although broadly in line with
ACIP recommendations [15, 16], age groups and
timing of vaccination vary between countries.
Funding of Pneumococcal Immunization
Programs
Further differences between countries across
Europe also relate to public reimbursement for
pneumococcal immunization. It is not funded
for any age or risk groups in Austria, Belgium, or
Luxembourg. Partial funding is available in
Denmark, Finland (stem cell transplantation
patients), Ireland (all individuals receiving PCV
\18 years of age and some patients receiving
PPV23 at risk of pneumococcal disease required
to pay an administration fee; no funding for
those aged C18 years), Norway (asplenia, HIV
and stem cell transplantation), and Sweden
(PCV13 funded in Stockholm county in
individuals at high risk of pneumococcal
diseases; PPV23 varies regionally between local
councils). In contrast, full public funding is
provided in France, Germany, Greece, Portugal,




The impact of pneumococcal immunization is
highly dependent on vaccine uptake.
Differences in pneumococcal immunization
recommendations can impact the rates of
immunization between countries. Risk-based
immunization programs require the
identification of individuals with specific
diseases, while targeting of vaccination is
simpler for age-based programs and thus they
are easier to implement. Countries with
age-based recommendations and public
Adv Ther
reimbursement have demonstrated a higher
uptake of PPV23 than countries immunizing
only individuals at risk of pneumococcal
diseases or countries without public
reimbursement [17].
A meta-analysis of the efficacy of PPV in
clinical trials demonstrated a high degree of
heterogeneity between trials with little
evidence of protection among elderly
individuals or adults with chronic respiratory
illness, for whom the vaccine was
recommended [18]. Similarly, a meta-analysis
of randomized controlled trials published up to
June 2012 demonstrated the effectiveness of
PPV in preventing IPD, but not all-cause
pneumonia or mortality in the elderly [19].
However, data are conflicting. For example, in
Japanese nursing home residents, PPV23 was
shown to reduce the prevalence of
pneumococcal pneumonia and all-cause
pneumonia, as well as decrease mortality
from pneumococcal pneumonia [20].
Although it is too early to assess the long-
term impact of the inclusion of PCV in adult
immunization programs, estimations can be
made based on impact data from PCV7
childhood immunization programs, which
have substantially reduced the burden of
pneumococcal diseases in children [7, 8].
Emerging impact data in children show a
decline in IPD due to serotypes contained in
PCV13, following the introduction of PCV13
in Spain, England, and Norway [21–23].
Furthermore, it is anticipated that PCV13 will
be cost-effective. Cost-effectiveness studies
have predicted net savings of 102 million
Euros over 5 years based on a model of a
65-year-old cohort immunization campaign in
Spain [24], and between 7 million and 19
million Euros based on a model of an age-
based PCV13 immunization program in adults
aged C65 years in Italy [25].
CONCLUSION
Young children and adults aged C50 years are at
particular risk of pneumococcal infection and
despite childhood and adult immunization
programs, burden of disease in adults remains
high. Since the approval of PCV13 in adults aged
C50 years in 2011, PCV13 is gradually being
included in recommendations for adult
pneumococcal immunization in addition to
inclusion in childhood immunization programs
within Western European countries. Ultimately,
this should help to increase vaccine uptake and
decrease the high burden of pneumococcal
diseases in adults both through a direct effect of
the vaccine and via a herd effect in unvaccinated
individuals. Vaccine uptake and the effectiveness
of pneumococcal immunization programs could
be somewhat increased by raising awareness
among healthcare professionals of the burden of
pneumococcal diseases in adults, and improving
the dissemination of recommendations for
pneumococcal immunization. Moreover,
the recommendations for pneumococcal
immunization can be very complex and vary
greatly between European countries in terms of
age, risk, and which vaccine should be
administered. When revising recommendations,
public health officials should consider clarifying
or simplifying recommendations, taking into
account the merits of age-based versus risk-based
recommendation for ease of implementation.
This could help to increase vaccine uptake
and thus reduce the burden of disease.
Furthermore, the Community Acquired
Pneumonia Immunization Trial in Adults
(CAPiTA; ClinicalTrials.gov #NCT00744263), a
randomized placebo-control trial involving
[84,000 pneumococcal vaccination-naı¨ve,
community-dwelling adults C65 years of age,
will provide valid data on the role of adult
PCV13 vaccination in preventing vaccine-type
Adv Ther
pneumococcal diseases, including pneumococcal
community-acquired pneumonia and IPD, and
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